Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo remains neutral on the stock and has a $45.00 price target.
Yanan Zhu has given Arcturus Therapeutics a Buy rating driven by a series of positive developments surrounding their ARCT-154 vaccine. Zhu views the Japanese regulatory approval of ARCT-154 as a significant validation of its competitive advantages over traditional mRNA vaccines, including its potential for higher immunogenicity and longer-lasting effects. This approval is expected to foster greater commercial success and adoption, given the vaccine’s promising clinical trial results and its endorsement by Japan’s MHLW for both initial and booster vaccinations for adults.
Furthermore, Zhu sees the broader regulatory progress of ARCT-154, with ongoing reviews by the EMA and anticipated commercial launches in multiple markets, as a positive trajectory for Arcturus. The vaccine’s proven efficacy, as demonstrated in clinical studies, and the company’s plans for updates on vaccines targeting new COVID-19 variants, lay the groundwork for sustained interest and potential market growth. Zhu’s Buy rating reflects these strategic advancements and the company’s prospects for commercialization and expansion in the coming years.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcturus Therapeutics (ARCT) Company Description:
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Read More on ARCT:
- Arcturus Therapeutics receives Orphan Drug Designation for ARCT-032 from FDA
- Arcturus Therapeutics treatment of cystic fibrosis granted orphan status
- Biotech Alert: Searches spiking for these stocks today
- Arcturus Therapeutics price target raised to $40 from $35 at Citi
- Arcturus Therapeutics reports Q3 EPS (61c), consensus ($1.69)
